Page 111 - Read Online

Page 10 of 12 Zhang et al. Hepatoma Res 2020;6:40 I http://dx.doi.org/10.20517/2394-5079.2020.20

56. Wilkie S, Picco G, Foster J, Davies DM, Julien S, et al. Retargeting of human T cells to tumor-associated MUC1: the evolution of a
chimeric antigen receptor. J Immunol 2008;180:4901-9.
57. Zhao L, Cao YJ. Engineered T cell therapy for cancer in the clinic. Front Immunol 2019;10:2250.
58. Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature 2017;545:423-31.
59. Gao H, Li K, Tu H, Pan X, Jiang H, et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
Clin Cancer Res 2014;20:6418-28.
60. Chen C, Li K, Jiang H, Song F, Gao H, et al. Development of T cells carrying two complementary chimeric antigen receptors against
glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. Cancer Immunol Immunother 2017;66:475-
89.
61. Pan Z, Di S, Shi B, Jiang H, Shi Z, et al. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells
by coexpression of a soluble PD1-CH3 fusion protein. Cancer Immunol Immunother 2018;67:1621-34.
62. Zhou F, Shang W, Yu X, Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev
2018;38:741-67.
63. Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, et al. Glypican 3 expression in human nonneoplastic, preneoplastic,
and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol 2008;129:899-906.
64. Zhai B, Shi D, Gao H, Qi X, Jiang H, et al. A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in
Chinese patients with refractory or relapsed GPC3 + hepatocellular carcinoma (r/r GPC3 + HCC). J Clin Oncol 2017;35:3049.
65. He Y, Hong Y, Mizejewski GJ. Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and
future prospects. Immunotherapy 2014;6:725-36.
66. Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, et al. Association between high-avidity T-cell receptors, induced by
α-fetoprotein-derived peptides, and anti-tumor effects in patients with hepatocellular carcinoma. Gastroenterology 2017;152:1395-406.
e10.
67. Liu H, Xu Y, Xiang J, Long L, Green S, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer.
Clin Cancer Res 2017;23:478-88.
68. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, et al. T cells targeting carcinoembryonic antigen can mediate regression of
metastatic colorectal cancer but induce severe transient colitis. Mol Ther 2011;19:620-6.
69. Xu Y, Yang Z, Horan LH, Zhang P, Liu L, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with
gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov 2018;4:62.
70. Lin KR, Deng FW, Jin YB, Chen XP, Pan YM, et al. T cell receptor repertoire profiling predicts the prognosis of HBV-associated
hepatocellular carcinoma. Cancer Med 2018;7:3755-62.
71. Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, et al. Immunotherapy of HCC metastases with autologous T cell receptor
redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol 2015;62:486-91.
72. Brechot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human
hepatocellular carcinoma. Nature 1980;286:533-5.
73. Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, et al. Engineering virus-specific T cells that target HBV infected hepatocytes and
hepatocellular carcinoma cell lines. J Hepatol 2011;55:103-10.
74. Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, et al. Use of expression profiles of HBV-DNA integrated into genomes of
hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology 2019;156:1862-76.e9.
75. Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, et al. TCR gene-modified T cells can efficiently treat established
hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 2016;65:293-304.
76. Zhu W, Peng Y, Wang L, Hong Y, Jiang X, et al. Identification of alpha-fetoprotein-specific T-cell receptors for hepatocellular carcinoma
immunotherapy. Hepatology 2018;68:574-89.
77. Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, et al. T cells engineered to express a T-cell receptor specific for
glypican-3 to recognize and kill hepatoma cells in vitro and in mice. Gastroenterology 2015;149:1042-52.
78. Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and
lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003;50:1281-4.
79. Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res
Clin Oncol 2006;132:293-301.
80. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, et al. Treatment of non-resectable hepatocellular carcinoma with autologous
tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002;17:889-96.
81. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, et al. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-
pulsed dendritic cells: a clinical trial. J Immunother 2005;28:496-504.
82. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with
tumor lysate in patients with hepatocellular carcinoma. Hepatology 2009;49:124-32.
83. El Ansary M, Mogawer S, Elhamid SA, Alwakil S, Aboelkasem F, et al. Immunotherapy by autologous dendritic cell vaccine in patients
with advanced HCC. J Cancer Res Clin Oncol 2013;139:39-48.
84. Kakumu S, Ito S, Ishikawa T, Mita Y, Tagaya T, et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular
carcinoma with hepatitis B and C virus infection. J Gastroenterol Hepatol 2000;15:431-6.
85. Tan XH, Zhu Q, Liu C, Liu XL, Shao XT, et al. Immunization with dendritic cells infected with human AFP adenovirus vector effectively
elicits immunity against mouse hepatocellular carcinomas. Zhonghua Zhong Liu Za Zhi 2006;28:13-6.